Teva Pharmaceutical Industries Limited (TEVA)
NYSE · Common stock · Pharmaceutical Preparations
As of Oct 21, 2:18 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow TEVA in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on TEVA and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
TEVA at a glance
Key statistics
$47.64B
Market capitalization
- Previous close
- $40.85
- Open
- $40.17
- Day range
- $39.54 – $41.08
- Volume
- 3.10M
- Average volume (30 sessions)
- 5.87M
- Shares outstanding
- 1.17B
- Price / earnings
- 67.4
- Earnings per share
- $0.61
- Price / book
- 6.2
- Price / sales
- 2.8
- Beta (1 year, vs SPY)
- 0.74
Where the price sits in its year
52-week range
94% of the range
- Below the 52-week high
- -3.2%
- Above the 52-week low
- +116.2%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $40.09+1.9%
- 50-day average
- $38.48+6.2%
- 200-day average
- $34.25+19.3%
Between the conventional 30 and 70 bands.
-1.0%
1 week
+2.0%
1 month
+35.5%
3 months
+30.9%
Year to date
+111.5%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with TEVA
TEVA on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on TEVA.
See the plans →
Every planScreen names like TEVA
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on TEVA
Put TEVA on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on TEVA
See whether there is an open premium alert on TEVA, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
TEVA headlines
- Teva to Host R&D Day on Wednesday, November 11 in New York City
GlobeNewswire Inc. · Oct 12, 2026
- Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
GlobeNewswire Inc. · Sep 23, 2026
- Teva Releases Q3 2026 Aide Memoire
GlobeNewswire Inc. · Sep 23, 2026
- New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
GlobeNewswire Inc. · Sep 18, 2026
- Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
GlobeNewswire Inc. · Sep 18, 2026
- Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
GlobeNewswire Inc. · Sep 18, 2026
- Teva Announces Launch of Offering of Senior Notes
GlobeNewswire Inc. · Sep 7, 2026
- Teva Releases Q2 2026 Aide Memoire
GlobeNewswire Inc. · Jun 18, 2026
SEC Form 4, most recent first
Insider filings
Savage Brian
+4.5K
Interim Chief Legal Officer · Option exercise
$156.25K · Sep 18, 2026
Savage Brian
−4.5K
Interim Chief Legal Officer · Option exercise
$156.25K · Sep 18, 2026
Savage Brian
−2.5K
Interim Chief Legal Officer · Open-market sale
$98.84K · Sep 18, 2026
MIGNONE ROBERTO
−367.6K
Director · Open-market sale
$14.36M · Sep 18, 2026
Savage Brian
−4.5K
Interim Chief Legal Officer · Open-market sale
$174.22K · Sep 18, 2026
Savage Brian
−314
Interim Chief Legal Officer · Open-market sale
$12.15K · Sep 18, 2026
Weiss Amir
−6.9K
Chief Accounting Officer · Open-market sale
$261.22K · Aug 21, 2026
Weiss Amir
−2.5K
Chief Accounting Officer · Open-market sale
$94.08K · Aug 21, 2026
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
- Exchange
- NYSE
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- Tel Aviv
- Employees
- 32,842
- Listed since
- Feb 16, 1982
- Website
- tevapharm.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.